Mosaic ImmunoEngineering Inc.
Mosaic ImmunoEngineering Inc. (CPMV): 1 pipeline candidate · ~3 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
2.5 months
D/E -1.00 · 0% dilution
Lead: Preclinical
1 candidate
N/A
N/A
A transparent, data-derived signal for Mosaic ImmunoEngineering Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$4.9M
Cash
$72
Quarterly Burn
$4K
Runway
2.5 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| MIE-101 | Preclinical |
Frequently asked questions
How many drug candidates are in Mosaic ImmunoEngineering Inc.'s pipeline?
Mosaic ImmunoEngineering Inc. (CPMV) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is Mosaic ImmunoEngineering Inc.'s lead drug candidate?
Mosaic ImmunoEngineering Inc.'s most advanced tracked candidate is MIE-101 (Preclinical) for Immuno-oncology; treatment of cancer via intratumoral administration to elicit anti-tumor immune response.
What is Mosaic ImmunoEngineering Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Mosaic ImmunoEngineering Inc. has approximately 2.5 months of cash runway.
What is Mosaic ImmunoEngineering Inc.'s market capitalization?
Mosaic ImmunoEngineering Inc.'s market capitalization is approximately $4.9M.
Who is the CEO of Mosaic ImmunoEngineering Inc.?
Mr. Steven W. King is the chief executive officer of Mosaic ImmunoEngineering Inc. (CPMV).
Get the full picture on Mosaic ImmunoEngineering Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.